SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0028 3835 "

Sökning: L773:0028 3835

  • Resultat 1-10 av 199
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Ahlman, Håkan, 1947, et al. (författare)
  • Interventional treatment of the carcinoid syndrome
  • 2004
  • Ingår i: Neuroendocrinology. - 0028-3835. ; 80 Suppl 1, s. 67-73
  • Tidskriftsartikel (refereegranskat)abstract
    • Liver metastases imply a major problem in patients with carcinoid tumours and hormone overproduction. Patients with distant metastases can undergo resection for potential cure or for symptom palliation. In patients with bilobar liver metastases other interventions are at hand, e.g. local ablation or hepatic arterial embolization. In selected cases liver transplantation can be a treatment alternative. Prior to all interventions patients with midgut carcinoids are protected with somatostatin analogues to reduce hormone secretion. Patients with foregut carcinoids may present special problems with life-threatening release of histamine during interventions.
  •  
2.
  •  
3.
  • Ahlstedt, Jonas, et al. (författare)
  • Non-invasive imaging methodologies for assessment of radiation damage to bone marrow and kidneys from peptide receptor radionuclide therapy. : -
  • 2019
  • Ingår i: Neuroendocrinology. - : S. Karger AG. - 1423-0194 .- 0028-3835. ; 110:1-2, s. 130-138
  • Tidskriftsartikel (refereegranskat)abstract
    • Background/Aims: Peptide receptor radionuclide therapy (PRRT) is becoming clinical routine for management of neuroendocrine tumours. The number of PRRT cycles is correlated with treatment effect but theoretically limited by off-target radiation damage to kidneys and bone marrow. New imaging biomarkers for assessment of PRRT tissue damage would enable evaluation of novel renal and bone marrow protective agents, as well as personalised PRRT treatment regiments. Methods: Mice treated with [177Lu]Lu-DOTA-TATE PRRT or vehicle were examined at baseline and following treatment with [18F]fluorothymidine (FLT) positron emission tomography (PET) and technetium-99m-mercapto-acetyl-tri-glycine ([99mTc]Tc-Mag3) single-photon emission tomography (SPECT) to assess dynamic changes in bone marrow proliferation and renal function, respectively. Results: Bone marrow proliferation as assessed by [18F]FLT was decreased 2 days after PRRT treatment, but not vehicle, compared to baseline (target-to-background ratio [TBRmax] baseline:1.69 ± 0.29 vs. TBRmax PRRT: 0.91 ± 0.02, p < 0.01). Renal function as assessed by [99mTc]Tc-Mag3 SPECT was similarly decreased 2 days following PRRT compared to vehicle (fractional uptake rate [FUR] vehicle: 0.030 ± 0.014 s–1 vs. FUR PRRT: 0.0051 ± 0.0028 s–1, p < 0.01). Conclusion: [18F]FLT PET and [99mTc]Tc-Mag3 SPECT are promising techniques for assessing bone marrow and renal injury from [177Lu]Lu-DOTA-TATE PRRT and may potentially improve patient management by allowing evaluation of protective interventions as well as enabling personalised PRRT treatments.
  •  
4.
  • Ahrén, K, et al. (författare)
  • Histamine stimulates progesterone synthesis and cyclic adenosine 3',5'-monophosphate accumulation in isolated preovulatory rat follicles
  • 1987
  • Ingår i: Neuroendocrinology. - : S. Karger AG. - 0028-3835 .- 1423-0194. ; 46:1, s. 69-74
  • Tidskriftsartikel (refereegranskat)abstract
    • The effect of histamine on progesterone synthesis and cyclic adenosine 3',5'-monophosphate (cAMP) accumulation was studied in superfused and incubated follicles dissected free from immature rats treated with pregnant mare serum gonadotrophin (PMSG). Histamine, like LH, increased the progesterone synthesis, but to a smaller extent. The H2-antagonist, cimetidine, inhibited completely the histamine-induced progesterone increase while the H1-antagonist, pyrilamine, as well as propranolol and atropine did not affect the initial response but modified its duration. The specific H2-agonist, 4-methylhistamine, but not the H1-agonist, 2-methylhistamine, mimicked the effect of histamine on progesterone synthesis. In the presence of the phosphodiesterase inhibitor, IBMX, histamine increased tissue levels of cAMP. These results suggest that histamine stimulates progesterone synthesis via the H2-receptor with cAMP acting as secondary intracellular messenger.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  • Anesten, Fredrik, et al. (författare)
  • Glucagon-Like Peptide-1-, but not Growth and Differentiation Factor 15-, Receptor Activation Increases the Number of Interleukin-6-Expressing Cells in the External Lateral Parabrachial Nucleus
  • 2019
  • Ingår i: Neuroendocrinology. - : S. Karger AG. - 0028-3835 .- 1423-0194. ; 109:4, s. 310-321
  • Tidskriftsartikel (refereegranskat)abstract
    • Interleukin (IL)-6 in the hypothalamus and hindbrain is an important downstream mediator of suppression of body weight and food intake by glucagon-like peptide-1 (GLP-1) receptor stimulation. CNS GLP-1 is produced almost exclusively in prepro-glucagon neurons in the nucleus of the solitary tract. These neurons innervate energy balance-regulating areas, such as the external lateral parabrachial nucleus (PBNel); essential for induction of anorexia. Using a validated novel IL-6-reporter mouse strain, we investigated the interactions in PBNel between GLP-1, IL-6, and calcitonin gene-related peptide (CGRP, a well-known mediator of anorexia). We show that PBNel GLP-1R-containing cells highly (to about 80%) overlap with IL-6-containing cells on both protein and mRNA level. Intraperitoneal administration of a GLP-1 analogue exendin-4 to mice increased the proportion of IL-6-containing cells in PBNel 3-fold, while there was no effect in the rest of the lateral parabrachial nucleus. In contrast, injections of an anorexigenic peptide growth and differentiation factor 15 (GDF15) markedly increased the proportion of CGRP-containing cells, while IL-6-containing cells were not affected. In summary, GLP-1R are found on IL-6-producing cells in PBNel, and GLP-1R stimulation leads to an increase in the proportion of cells with IL-6-reporter fluorescence, supporting IL-6 mediation of GLP-1 effects on energy balance.
  •  
9.
  • Anthony, Lowell B., et al. (författare)
  • Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors : Analysis from the Phase III RADIANT-2 Trial
  • 2015
  • Ingår i: Neuroendocrinology. - : S. Karger AG. - 0028-3835 .- 1423-0194. ; 102:1-2, s. 18-25
  • Tidskriftsartikel (refereegranskat)abstract
    • Background/Aims: The phase III placebo-controlled RADI-ANT-2 trial investigated the efficacy of everolimus plus octreotide long-acting repeatable (LAR) in patients with advanced neuroendocrine tumors (NET) associated with carcinoid syndrome. Here we report a secondary analysis based on the previous somatostatin analogue (SSA) exposure status of patients enrolled in RADIANT-2. Methods: Patients were randomly assigned to receive oral everolimus 10 mg/day plus octreotide LAR 30 mg intramuscularly (i.m.) or to receive matching placebo plus octreotide LAR 30 mg i.m. every 28 days. SSA treatment before study enrollment was permitted. Patient characteristics and progression-free survival (PFS) were analyzed by treatment arm and previous SSA exposure status. Results: Of the 429 patients enrolled in RADI-ANT-2, 339 were previously exposed to SSA (95% received octreotide); 173 of 339 patients were in the everolimus plus octreotide LAR arm. All patients had a protocol-specified history of secretory symptoms, but analysis by type showed that more patients who previously received SSA therapy had a history of flushing symptoms (77%), diarrhea (86%), or both (63%) compared with SSA-naive patients (62, 62, and 24%, respectively). Patients who received everolimus plus octreotide LAR had longer median PFS regardless of previous SSA exposure (with: PFS 14.3 months, 95% confidence interval, CI, 12.0-20.1; without: 25.2 months, 95% CI, 12.0-not reached) compared with patients who received placebo plus octreotide LAR (with: 11.1 months, 95% CI, 8.4-14.6; without: 13.6 months, 95% CI, 8.2-22.7). Conclusion: Everolimus in combination with octreotide improves PFS in patients with advanced NET associated with carcinoid syndrome, regardless of previous SSA exposure.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 199
Typ av publikation
tidskriftsartikel (185)
konferensbidrag (7)
forskningsöversikt (7)
Typ av innehåll
refereegranskat (152)
övrigt vetenskapligt/konstnärligt (47)
Författare/redaktör
Öberg, Kjell (32)
Eriksson, Barbro (26)
Welin, Staffan (25)
Tiensuu Janson, Eva (16)
Sundin, Anders, 1954 ... (16)
Kaltsas, Gregory (13)
visa fler...
Öberg, Kjell, 1946- (13)
Sundin, Anders (12)
Knigge, U. (12)
Kos-Kudła, Beata (11)
Falconi, Massimo (11)
Pavel, M. (11)
Hellman, Per (10)
O'Toole, Dermot (10)
Wiedenmann, Bertram (10)
Pavel, Marianne (10)
Caplin, Martyn (10)
Plöckinger, Ursula (10)
Caplin, M. (10)
Ruszniewski, P (10)
Scoazec, Jean-Yves (9)
Bodei, Lisa (9)
Gross, David (9)
Falkerby, Jenny (9)
Rindi, Guido (9)
Kaltsas, G. (9)
Ahlman, Håkan, 1947 (8)
Nilsson, Ola, 1957 (8)
Salazar, Ramon (8)
Perren, Aurel (7)
Granberg, Dan (7)
Grossman, Ashley (7)
Crona, Joakim (7)
Rindi, G (7)
Fazio, Nicola (7)
O'Toole, D. (7)
Kianmanesh, R. (7)
Couvelard, Anne (7)
Sorbye, Halfdan (6)
Norlén, Olov (6)
Jensen, Robert T. (6)
Grozinsky-Glasberg, ... (6)
de Herder, Wouter W (6)
Arnold, Rudolf (6)
Costa, Frederico (6)
Modlin, Irvin M. (6)
Rinke, Anja (6)
Daskalakis, Kosmas (6)
Arnold, R (6)
Delle Fave, Gianfran ... (6)
visa färre...
Lärosäte
Uppsala universitet (139)
Karolinska Institutet (46)
Göteborgs universitet (18)
Lunds universitet (11)
Umeå universitet (9)
Linköpings universitet (4)
visa fler...
Örebro universitet (2)
Chalmers tekniska högskola (1)
Röda Korsets Högskola (1)
visa färre...
Språk
Engelska (199)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (125)
Naturvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy